Vascular reactivity in diabetes mellitus

PARESH DANDONA

Division of Endocrinology and Metabolism. State University of New York at Buffalo. USA.

INTRODUCTION

A patient with type 2 diabetes carries a cardiovascular risk similar to that of a non-diabetic with a prior history of myocardial infarction. Endothelial dysfunction, an early event in the pathogenesis of atherosclerosis is present in diabetes mellitus in the absence of clinical cardiovascular disease. The assessment of the endothelium dependent vasodilatory effect in response to various stimuli known to increase NO (nitric oxide) production is termed vascular reactivity.

Vascular reactivity has been assessed in conduit arteries, forearm resistance vessels capillaries and vein in diabetes. The cerebral, myocardial, skeletal muscle, renal, skin and penile blood vessels in type 1 and type 2 diabetes have been shown to have abnormal vascular reactivity. It is possible that impaired vascular reactivity may contribute to the clinical manifestations of cardiovascular disease, the pathogenesis of nephropathy, diastolic dysfunction, foot ulcers and erectile dysfunction in subjects with diabetes mellitus.

MEDIATORS OF VASODILATION

There are two major vasodilators that are secreted by the endothelium (fig. 1). Endothelial cells express nitric oxide synthase that generates NO in response to a variety of stimuli including acetyl-choline, nor-epinephrine and insulin. Glucose suppresses the expression of e-NOS and NO release while insulin increases it. Therefore in diabetes the combination of hyperglycemia, insulin lack and insulin resistance results in diminished NOS expression and secretion and thus to impaired vasodilation.

NO exerts its vasodilatory effect through the stimulation of guanylate cyclase, which induces an increase in cGMP (cyclic guanosine monophosphate) which is a vascular smooth muscle relaxant. In diabetes, NOS may undergo alterations due to the binding of N-acetyl glucosamine which prevents the essential serine phosphorylation necessary for its action. Furthermore, there may be a reduction in the availability of tetrahydro-biopterin necessary for NO to be generated by NOS. THB levels are reduced in diabetes.
because it is destroyed by oxidative stress. In oxidative stress states, NOS can also cause nitration of prosta-
cyclin synthase and impair its ability to generate PGI2
(prostacyclin 2)1,3.

Similarly, there is a diminution in the ability of the
dermalium to generate PGI2 in diabetes. This again
contributes to an overall pro-constrictor state in dia-
bes. Glucose inhibits PGI2 production by endothelial
cells and arteries obtained from animals rendered dia-
betic generate less PGI23.

MEDIATORS OF VASOCONSTRICTION

The major vasoconstrictors are norepinephrine, an-
giotensin II, endothelin, thromboxane A2 and 5-
hydroxyeicosatetraenoic acid. Endothelin –I is in-
creased in type 2 diabetes mellitus, however vascular
response to endothelin is decreased in this disease. In
the obese, angiotensinogen secretion is increased since
the adipocyte expresses this protein and secretes it.
Thus, the basic substrate for angiotensin generation is
in excess. Its conversion to angiotensin I and II would
thus lead to a proconstrictor state. Angiotensin II can
increase free radical generation; impair NO generation
and cause smooth muscle contraction. Moreover an-
giotensin receptor blockers and ace inhibitors have
been associated with improved endothelial function
and better cardiovascular outcomes in clinical studies
of subjects with type 2 diabetes3.

Oxidative stress reduces the bio-availability of NO
since NO binds avidly to the superoxide radical to
form peroxynitrate. This is likely to have an effect on
vascular reactivity. With oxidative stress following a
fast food meal, normal post ischemic vasodilation
changes to a markedly impaired one. Elevated plasma
free fatty acid concentration induces abnormal vascu-
lar reactivity within two hours in association with a
marked increase in NADPH oxidase dependent ROS
generation. Inflammatory stress is also associated
with impaired vascular reactivity. Indeed, there is an
inverse relationship between plasma CRP concentra-
tion and post ischemic brachial vasodilation. Pro-in-
flammatory cytokines like TNFα are known to reduce
the expression of NOS in the endothelium and to lead
to a reduction in the generation of NO by the endo-
thelium1.

RELATIONSHIP OF VASCULAR REACTIVITY
WITH ATHEROSCLEROSIS

The positive predictive value of abnormal brachial
artery dilation (< 3%) in predicting coronary endothe-

dysfunction is 95%. FMD% is also predictive of
corona artery disease. Post-ischemic brachial arter-
ial vasodilation is impaired in diabetes and is therefore
predictive of cardiovascular events7.
Dandona P. Vascular reactivity in diabetes mellitus

Endothelial dysfunction occurs early, can be measured noninvasively and improvement of glycemic control and lowering of cholesterol shown to decrease cardiovascular events in clinical studies have also improved endothelial dysfunction in diabetes and dyslipidemic conditions. This technique could thus be used as an additional marker for assessing the risk of CAD in this population. As endothelial function can be impaired by factors other than hyperglycemia, the choice of antihyperglycemic, antihypertensive, lipid lowering therapy and the goals of these therapy could be determined on this assessment.

EFFECTS OF INSULIN AND THIAZOLIDENEDIONE ON VASCULAR REACTIVITY AND ATHEROSCLEROSIS

While the abnormality of post ischemic brachial vasodilation is well established, it has also been shown that following thiazolidenedione therapy, there is a restoration towards normality. This reversal occurs over a period of only four weeks and hence the abnormality of vascular reactivity in obesity and type 2 diabetes is not due to a structural change. Thiazolidenediones are known to suppress ROS generation and thus to reduce superoxide. In addition, they also exert an anti-inflammatory effect, which suppresses pro-inflammatory cytokines. Both of these effects are likely to induce an enhancing affect on NO bioavailability and thus to potentially contribute to the improvement in vascular reactivity.

Since insulin also exerts a profound suppressive effect on NADPH oxidase dependent superoxide generation and NFkB dependent inflammation, it should be expected to improve post ischemic vasodilatory responses in the obese and type 2 diabetics. While insulin is known to exert a definitive vasodilatory effect its ability reverse abnormalities in vascular reactivity in the obese and type 2 diabetics needs to be investigated. The profound ROS suppressive and anti-inflammatory effects of insulin have been demonstrated also in patients with acute myocardial infarction and those undergoing coronary artery bypass grafts.

CONCLUSIONS

Impaired vascular reactivity by invasive and noninvasive methods has been shown in different vascular beds in type 1 and type 2 diabetes mellitus. It is probable that impaired vascular reactivity contributes to atherosclerosis and the pathogenesis and progression of the clinical manifestations of cardiovascular disease like acute coronary syndrome and stroke. It may also play a role in the pathogenesis of diastolic dysfunction, nephropathy, foot ulcers and erectile dysfunction. Resistance to the beneficial vasodilatory effects of insulin and increased reactive oxygen species generation due to various factors are probably responsible for the decreased bioavailability of NO and impaired vascular reactivity seen in diabetes. Improved glycemic control, insulin sensitizers, HMG CoA reductase inhibitors, fibric acid derivatives, ACE inhibitors and angiotensin receptor blockers, improve endothelial function and have also improved cardiovascular outcomes in clinical studies. Non-invasive assessment of vascular reactivity can thus be used, as a surrogate marker of coronary endothelial dysfunction, is reproducible and could reflect a treatment benefit if an intervention improves brachial dilatation.

Conflict of interest

The author declares he is supported by:
- Department of Citrus, State of Florida.
- NIH - R01DK069805-02; RO-1DK.
- NIH - 1 R01 DK075877-01A2.

REFERENCES